|
 |
VisipaqueThis page contains recent news articles, when available, and an overview of Visipaque but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.A first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of GE Healthcare's ... Medical News Today - Medical News Today (press release) TCT: Low-Osmolar Contrast Agents Don't Increase Nephropathy Risk - Oct 26, 2006 WASHINGTON, Oct. 26 -- The use of Visipaque (iodixanol), an iso-osmolar, nonionic contrast agent, did not reduce the rate of nephropathy in angiography ... MedPage Today In contrast with 1990s, media prices set to rise. - May 1, 2005 Visipaque is a nonionic, isosmolar contrast medium used to provide enhanced X-ray images of soft tissues, primarily blood vessels and organs. ... $4.95 - Hospital Materials Management - ECNext Study shows GE Healthcare's VisipaqueTM Associated with Lower … - Nov 21, 2008 ..."This study reinforces why we believe that Visipaque is an appropriate ... "The lower incidence of CIN associated with Visipaque seen in this study is ... International Business Times GE Healthcare dan Sistem Kesehatan Manipal Lakukan Kajian Klinis … - Jun 30, 2006 Walaupun resiko reaksi serius dengan Visipaque dianggap rendah, media kontras teryodium ... Keselamatan dari Visipaque dalam kehamilan belum ditetapkan. ... ANTARA GE Healthcare dan Sistem Kesehatan Manipal Lakukan Kajian Klinis … - Jun 30, 2006 Kajian pertama akan berfokus pada Visipaque (iodixanol) obat pelawan isosmolar yang ... Saat ini, Visipaque telah digunakan pada jutaan prosedur sinar X dan ... ANTARA Iodixanol vs Iopromide Study Abstract Presented at American College... - Apr 1, 2008 In the US, Visipaqueâ„¢ (iodixanol) Injection Nonionic Isosmolar VISIPAQUE IS NOT FOR INTRATHECAL USE. All nonionic, iodinated contrast media currently ... Web Services Journal - Web Services Journal GE Healthcare Collaborates With Manipal Health Systems to Conduct … - Jun 30, 2006 The first studies will focus on Visipaque(TM) (iodixanol) an isosmolar contrast ... Visipaque has been used in millions of X-ray and computer tomography ... Newswit.com GE opens development centre in India to study medical diagnostic … - Jul 13, 2006 The first studies will focus on Visipaque (iodixanol) an isosmolar contrast agent ... Visipaque has been used in millions of X-ray and computer tomography ... MTBeurope Risk of contrast-induced nephropathy in patients with normal renal … - Jan 12, 2007 ...gender and diabetes, participants were randomized to receive the nonionic, iso-osmolar dimeric contrast medium iodixanol (Visipaque ® , GE Healthcare, ... Nature.com Detection of an aortoenteric fistula in a patient with intermittent... - May 1, 2008 Multidetector CT (MDCT) was performed with 90 ml of contrast medium (Visipaque ® ; GE Healthcare, Oslo, Norway), which was administered through the ... Nature.com GE Healthcare's 1st clinical studies centre in B'lore - Jun 29, 2006 The first study will focus on Visipaque, a contrast agent that was launched globally by GE Healthcare in 1996. Contrast agents are used during medical ... Business Standard AKER KVAERNER WINS 'FULL-DENSITY' PE DEAL - Oct 10, 2005 Products involved include x-ray and magnetic resonance imaging products Visipaque, Omnipaque and Omniscan. The China plant will serve GE customers around ... ICIS Guerbet - Another Proof That There is no Difference Between Low- … - Oct 27, 2007 WASHINGTON, DC -- October 27, 2007 -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) ... DG News GE boosts contrast media plant in China.(GE Healthcare )(Brief... - Oct 10, 2005 Products involved include x-ray and magnetic resonance imaging products Visipaque, Omnipaque and Omniscan. The China plant will serve GE customers around ... Free with registration - ECN-European Chemical News - AccessMyLibrary.com Iodixanol unexpectedly linked to higher renal failure rates.( … - Dec 15, 2005 Among 47543 patients for whom iodixanol (Visipaque) was used, rehospitalization with renal failure was about twice as common: 1108 patients or 2.3%. ... Free with registration - Internal Medicine News - AccessMyLibrary.com PLC Presents Two Abstracts at CRT 2007. - Mar 7, 2007 Each received contrast doses ranging from 50 to 200 ml of Visipaque, and standard doses of Mucomyst (acetylcysteine) and sodium bicarbonate. ... $4.95 - PR Newswire - ECNext Iso-osmolar X-ray dye falters in PCI study - Apr 1, 2008 Some earlier studies have shown that iodixanol (Visipaque) reduces the risk of kidney damage when moderate doses of x-ray dye, or contrast medium, are used, ... Genetic Engineering News - Genetic Engineering News (press release) Article: Britney's latest head line.(Features) - Huddersfield Daily... - Feb 21, 2007 ...and Visipaque([TM320 (iodixanol injection), marketed by GE Healthcare in the United States, in renally Im paired Pa tients undergoing C omputed ... Pay-Per-View - Huddersfield Daily Examiner - HighBeam Research Published Study Demonstrates Lower Serum Creatinine Levels after … - Jul 16, 2008 VISIPAQUE had a trend toward fewer patient reports of moderate or severe pain or warmth; however, whether or not this is related to the dose, ... Genetic Engineering News - Genetic Engineering News (press release) GE Healthcare Invests US$37.5 Million in Chinese Bio-Sciences … - Sep 23, 2005 Today, the Shanghai facility manufactures close to five million units of GE Healthcare's X-Ray and magnetic resonance imaging (MRI) products; Visipaque(TM), ... $4.95 - Business Wire - ECNext Product Briefs - Nov 2, 2006 ...marketed by Bracco in the US, and Visipaque-320 (iodixanol injection), marketed by GE Healthcare (Waukesha, Wisconsin) in the US, in renally impaired ... Free with registration - Medical Device Week - AccessMyLibrary.com Global top 20 medical packaging companies ranked by total revenue in ... - Jul 1, 2007 ...worldwide dir of Ethicon package development Endo-Surgery; DePuy; Cordis; LifeScan 2 GE Healthcare Donald Shervey, TruScan; Visipaque; Waukesha, Wis. ... $20.00 - Food & Drug Packaging - Alacra Store Radiological Case: Constrictive Pericarditis - Jun 9, 2008 Waukesha, WI), a CT pulmonary angiogram was performed with intravenous infusion of contrast (Visipaque 320 mgI/mL, GE Healthcare, Princeton, NJ). ... Medscape Visualizing a healthier world.(TOP 200 PACKAGERS: MEDICAL: #2: GE … - Jul 1, 2005 From a packaging perspective, last July the company added to its Omnipaque[TM] (iohexol) and Visipaque (iodixanol) product packaging portfolios with the ... $4.95 - Food & Drug Packaging - ECNext Press Release: PLC Presents Two Abstracts at CRT 2007. - PR Newswire … - Mar 7, 2007 Each received contrast doses ranging from 50 to 200 ml of Visipaque, and standard doses of Mucomyst (acetylcysteine) and sodium bicarbonate. ... Pay-Per-View - PR Newswire - HighBeam Research Iso-osmolar X-ray dye falters in PCI research - Apr 3, 2008 Some earlier studies have shown that iodixanol (Visipaque) reduces the risk of kidney damage when moderate doses of X-ray dye, or contrast medium, are used, ... Science Centric The Insider: Walkers can't do enough good work, VC lawyer can't get … - Nov 6, 2006 Text: Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol) were no different in ... nwsource.com Top 200 drugs used in hospitals in 2006.(Table) - Apr 16, 2007 Cipro I.V. 115976664.00 10.38 73 Merrem 115841953.50 90.40 74 NovoSeven 115306156.89 23.29 75 Visipaque 114583924.71 2.89 76 Activase 114354622.77 27.62 ... $4.95 - Drug Topics - ECNext Article: Visualizing a healthier world.(TOP 200 PACKAGERS: MEDICAL: #... - Jul 1, 2005 Buckinghamshire, U.K ... development Endo-Surgery; DePuy; Cordis; LifeScan 2 GE Healthcare Donald Shervey, TruScan; Visipaque; Waukesha, Wis ... ... Pay-Per-View - Food & Drug Packaging - HighBeam Research The Latest Head-to-Head Clinical Study Comparing the Risk of CIN … - Oct 31, 2006 ...marketed by Bracco Diagnostics Inc. in the United States, and Visipaque([TM])-320 (iodixanol injection), marketed by GE Healthcare in the United States, ... Free with registration - Business Wire - AccessMyLibrary.com $37.5M expansion for GE's Shanghai plant. - Oct 3, 2005 ...facility manufactures close to five million units of GE Healthcare's X-ray and magnetic resonance imaging products: Visipaque, Omnipaque and Omniscan. ... $4.95 - Pharma Marketletter - ECNext In contrast with 1990s, media prices set to rise. | Article from... - May 1, 2005 Based on evaluations conducted at 30 Consorta hospitals, Amersham was selected to provide its Omnipaque[TM], Visipaque ... ... Pay-Per-View - Hospital Materials Management - HighBeam Research Klikk pÃ¥ kroppen: - Jul 4, 2007 ...til Ã¥ svelge i "vranga" eller er nyoperert i omrÃ¥det, er det viktig Ã¥ si i fra om dette slik at man kan bruke et trygt jodkontrastmiddel (Visipaque). ... Rikshospitalet United States top 200 brand and generic drugs used in hospitals in … - Jun 19, 2006 Omeprazole 115101383.84 174.23 171 Albuterol 114437278.09 28.51 172 Visipaque 114411096.68 10.09 173 Mirena 114140399.53 32.35 174 Xalatan 113925199.85 ... $20.00 - Drug Topics - Alacra Store Le colorant pour rayon-X Iso-osmolaire bat de l'ail dans l'étude sur... - May 15, 2008 Certaines études antérieures avaient révélé que l'iodixanol (Visipaque) réduit le risque de lésions rénales lorsque des doses modérées – ou milieu de ... InformationHospitaliere.com Product Briefs. - Dec 1, 2006 ...and Visipaque-320 (iodixanol injection), marketed by GE Healthcare (Waukesha, Wisconsin) in the U.S., in renally impaired patients undergoing computed ... $9.94 - Biomedical Business & Technology - Alacra Store '가스트로그ë?¼í•€' 등 21종 대ìƒ? - Jun 3, 2005 ...입찰품목ì?€ '가스트로그ë?¼í•€' 등 ì‰?ë§? ì œí’ˆ 9종, '가소콜' 등 íƒœì¤€ì œì•½ ì œí’ˆ 9 종, 'VISIPAQUE' 등 아머샴 ì œí’ˆ 2종, ê²Œë¥´ë² ì½”ë¦¬ì•„ '리피오ë?Œ' 등으로 구성ë?¼ 있다. 디지틀보사 Ausbeutung junger Ärztinnen und Ärzte - Jul 25, 2008 ...von Visipaque am 25.07.2008 12:36:13. Gibt es da einen Tarif, oder ist das Gehalt frei verhandelbar. Habe mehrjährige radiologische Erfahrung und nicht mehr ... Deutsches Ärzteblatt Press Release: Guerbet - Another Proof That There is no Difference … - Oct 27, 2006 WASHINGTON, October 27 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) ... Pay-Per-View - PR Newswire - HighBeam Research Johns Hopkins University, US Medical study results announced by Johns... - Dec 5, 2006 ..."Contrast-enhanced (Visipaque, 150 mL, 325 mg/mL) MDCT (0.5 mm x 32 slice) was performed before occlusion and 90 minutes (canine) or 8 weeks (porcine) after ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Imaging; Acute, healed myocardial infarction extent was quantified by... - Mar 14, 2006 ..."Contrast-enhanced (Visipaque, 150 mL, 325 mg/mL) MDCT (0.5 mm x 32 slice) was performed before occlusion and 90 minutes (canine) or 8 weeks (porcine) after ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones COMUNICADO: Guerbet: Nuevos datos sobre la prevención de la … - Oct 27, 2006 Los resultados de un reciente ensayo clÃnico demostraron que los agentes de contraste Hexabrix(R) (Ioxaglato) y Visipaque(R) (Iodixanol) no fueron ... elEconomista.es GE Healthcare presenta sus nuevas tecnologÃas - May 9, 2006 ...-con el Discovery VCT-, la resonancia magnética Signa HDx, y los agentes de contraste, tales como Visipaque (Rayos X) y Omniscan (Resonancia Magnética). doyma.es |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |